Norgine acquires Danish firm Azanta

25 March 2020

Netherlands-based Norgine says it has acquired Azanta, a Denmark-based specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine.

As a result of the transaction, financial terms of which were not disclosed, Norgine acquires Azanta’s portfolio of products, including Angusta (misoprostol) a for labor induction and n0imorazole, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. Angusta was approved in first-quarter 2017 in the Nordics, and in the fourth quarter of 2017 in France and 10 CEE countries. Regulatory approval for the rest of Europe is expected to be filed in first-half 2020. Nimorazole has European Medicines Agency orphan drug status and is ready for Phase III stage development

Back in 2014, Norgine Ventures provided Azanta with financing of up to 7 million euros ($8.8 million at then exchange rates) to help it fund its late-stage clinical development pipeline and grow commercial sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK